WO2004087095A3 - Osmotic controlled release device containing zafirlukast and an h1-antagonist - Google Patents

Osmotic controlled release device containing zafirlukast and an h1-antagonist Download PDF

Info

Publication number
WO2004087095A3
WO2004087095A3 PCT/CR2004/000004 CR2004000004W WO2004087095A3 WO 2004087095 A3 WO2004087095 A3 WO 2004087095A3 CR 2004000004 W CR2004000004 W CR 2004000004W WO 2004087095 A3 WO2004087095 A3 WO 2004087095A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
zafirlukast
controlled release
release device
device containing
Prior art date
Application number
PCT/CR2004/000004
Other languages
Spanish (es)
French (fr)
Other versions
WO2004087095A2 (en
Inventor
Juan A Vergez
Joaquina Faour
Marcelo F Befumo
Original Assignee
Osmotica Costa Rica Sa
Juan A Vergez
Joaquina Faour
Marcelo F Befumo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Costa Rica Sa, Juan A Vergez, Joaquina Faour, Marcelo F Befumo filed Critical Osmotica Costa Rica Sa
Publication of WO2004087095A2 publication Critical patent/WO2004087095A2/en
Publication of WO2004087095A3 publication Critical patent/WO2004087095A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

The invention relates to a controlled release device, e.g. an osmotic device, which releases zafirlukast in a controlled manner and which releases a H1 antagonist in a rapid and/or immediate manner. A wide range of antihistamine H1 antagonists, particularly loratadine, can be used in the inventive device. Specific embodiments of the invention comprise osmotic devices which release zafirlukast and a H1 antagonist in a controlled manner from the nucleus over an extended period of time. The aforementioned devices can be used for the treatment of allergic reactions, inflammation and asthma.
PCT/CR2004/000004 2003-03-31 2004-03-30 Osmotic controlled release device containing zafirlukast and an h1-antagonist WO2004087095A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45909803P 2003-03-31 2003-03-31
US60/459,098 2003-03-31

Publications (2)

Publication Number Publication Date
WO2004087095A2 WO2004087095A2 (en) 2004-10-14
WO2004087095A3 true WO2004087095A3 (en) 2005-07-21

Family

ID=33131864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CR2004/000004 WO2004087095A2 (en) 2003-03-31 2004-03-30 Osmotic controlled release device containing zafirlukast and an h1-antagonist

Country Status (1)

Country Link
WO (1) WO2004087095A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620863A8 (en) 2005-12-29 2018-01-16 Osmotica Kereskedelmi Es Szolgaltato Kft triple-release combination tablet
CN104958279A (en) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 Loratadine oral quickly-soluble film and preparation method thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO1997028797A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composion
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US20020102305A1 (en) * 2000-01-13 2002-08-01 Joaquina Faour Osmotic device containing pseudoephedrine and an H1antagonist
CA2337571A1 (en) * 2001-02-20 2002-08-20 Asta Medica Aktiengesellschaft Antihistamine leukotriene combinations
WO2002080916A1 (en) * 2001-04-03 2002-10-17 Kaura Sita R Composition and method for the treatment of respiratory disease
US20030044457A1 (en) * 2001-07-17 2003-03-06 Joaquina Faour Drug delivery device containing oseltamivir and an H1 antagonist
US20030055077A1 (en) * 2000-04-12 2003-03-20 Jones Thomas R. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
WO2003068186A1 (en) * 2002-02-11 2003-08-21 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO1997028797A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composion
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US20020102305A1 (en) * 2000-01-13 2002-08-01 Joaquina Faour Osmotic device containing pseudoephedrine and an H1antagonist
US20030055077A1 (en) * 2000-04-12 2003-03-20 Jones Thomas R. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
CA2337571A1 (en) * 2001-02-20 2002-08-20 Asta Medica Aktiengesellschaft Antihistamine leukotriene combinations
WO2002080916A1 (en) * 2001-04-03 2002-10-17 Kaura Sita R Composition and method for the treatment of respiratory disease
US20030044457A1 (en) * 2001-07-17 2003-03-06 Joaquina Faour Drug delivery device containing oseltamivir and an H1 antagonist
WO2003068186A1 (en) * 2002-02-11 2003-08-21 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
WO2004087095A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
EG25026A (en) Device for storing tubulars and devices for handling of tubulars.
EP1710696B8 (en) Semiconductor device and method for activating the same
EP1942905A4 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
EP1874301A4 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP1824812A4 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
WO2006116348A3 (en) Compositions for medical devices containing agent combinations in controlled volumes
IL187163A (en) Fluorene derivatives, compositions containing said derivatives and the use thereof
ZA200710645B (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP1904143A4 (en) Embolic protection device and methods of use
EP1776148A4 (en) Ophthalmic devices and related methods and compositions
EP1941558A4 (en) Piezoelectric device, method of actuating the same, piezoelectric apparatus, and liquid discharge apparatus
EP1608361A4 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
EP1756949A4 (en) Semiconductor device and method of forming the same
IS7186A (en) Quinuclidine derivatives, their production methods and their use as M2 and / or M3 muscarinic receptor inhibitors
ZA200708544B (en) Nanoparticulate corticosteroid and antihistamine formulations
EP1868985A4 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TWI368320B (en) Solid state imaging device, manufacturing method of the same, and substrate for solid state imaging device
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
EP1971602A4 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP1751175A4 (en) Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1717246B8 (en) Tnf antagonists and tnf inhibitors comprising the same as the active ingredient
TWI366779B (en) Pointing device and the method of emulating pointing device
EP1940402A4 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase